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1. Introduction
Recent studies have hypothesized that brain tumor stem cells (BTSCs) are responsible for the
poor survival outcome of brain tumor patients. Sonic hedgehog (Shh) is one of the crucial
signaling pathways to regulate stem cell self-renewable capacity. Disruption of this pathway
activate Gli transcription factors, which further activate other downstream target genes
including BMI1 to promote brain tumor development (medulloblastoma and glioblastoma
among other tumors) (Leung et al., 2004; Bruggeman et al., 2007; Godlewski et al., 2008). BMI1
is a polycomb complex protein also known as polycomb group RING finger protein 4 (PCGF4)
or RING finger protein 51 (RNF51). BMI1 gene (B cell-specific Moloney Murin leukemia virus
integration site 1) is located on human chromosome 10 (10p13). Interestingly, BMI1 showed
high expression in medulloblastoma and glioblastoma (Leung et al., 2004; Natsume et al., 2011).
Shh treatment induced both BMI1 and Gli1 expression. Gli1 overexpression also promoted
high expression of BMI1. High expression of BMI1 in tumor cells indicates high capacity of
self-renewing characteristics (Hemmati et al., 2003). Most of the BTSCs showed high expression
of BMI1. Inhibition of Gli with specific inhibitor GANT61 and Gli siRNAs mediated knock‐
down inhibited brain tumor cell proliferation and also decreased the expression of BMI1 in
medulloblastoma and glioblastoma (Shahi et al., unpublished). Therefore, all these studies
suggest that BMI1 would be a novel therapeutic transcription factor to target BTSCs and
enhance the survival of brain tumor patients.
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2. BMI1: An oncogene and stem cell marker
BMI1 is one of the crucial genes for the development of various tissues including the nervous
system. This gene is located at chromosome 10p13 in humans. BMI1 was initially identified as
a murin leukemia viral oncogene [1]. BMI1 was the first gene reported to belong to the
Polycomb-group of genes [2]. These genes express the proteins which form a large multimeric
structure to silence other genes via modification in chromatin organization [3]. Polycomb
repressive complexes are divided into two groups.
Polycomb repressive complex 1 (PRC1)
Polycomb repressive complex 2 (PRC2)
PRC1 includes BMI1, and PRC2 includes enhancer of zeste homolog 2 (EZHZ) to facilitate
stable silencing of gene expression [4]
3. Role of BMI1 in normal development
BMI1 polycomb protein is essential for the self-renewal of stem cells of different tissues of the
body besides the central nervous system (CNS) [5]. One study showed that Nestin-BMI1-GFP
transgenic mice cells increased the development of neural stem cell colonies and the self-
renewal capability of fetal and adult CNS cells (He et al., 2009). Ink4a and Arf genes encode
tumor suppressor proteins p16Ink4a and p19Arf respectively, which are involved in the
inhibition of cell cycle progression [6]. Interestingly, BMI1 promotes the maintenance of CNS
stem cells from the embryonic stage to adulthood by suppressing Ink4a and Arf genes [5].
BMI1 is also involved in Shh signaling mediated postnatal cerebellar neurogenesis by binding
to the promoter of p21waf1/cip1 [7]. Moreover, BMI1 is a crucial gene for the development of
embryonic and adult stem cells and brain tumors. Interestingly, selective conditional knockout
of BMI1 based on Cre/LoXP in transgenic mouse showed that BMI1 has potential to induce
neural stem cells proliferation and self-renewal both in vitro and in vivo [8]. In this process
BMI1 down-regulates both Ink4a/ARF and p21/FoxG1. Moreover, increased ectopic expression
of BMI1 in progenitors committed to a neuronal lineage during embryonic cortical develop‐
ment, triggered apoptosis via a survivin-mediated mechanism, and caused a reduction in brain
size [8]. However, the self-renewable capability of adult neural stem progenitor cells is
independent of FoxG1, while apoptosis resistance of neural progenitor cells depends on high
expression of BMI1 [8].
4. Role of BMI1 in glioblastoma development
Gliomas are the most common brain tumors of the central nervous system comprising
astrocytic gliomas, oligodendrogliomas, or a mixture of both. The most malignant glioma is
glioblastoma multiforme (GBM) (WHO grade IV) comprising about 50% of glioma. Post-
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therapy survival rate of GBM patients is 24% for 1 year and 12% for 2 years only [9]. There are
ample amount of evidence suggesting that gliomas have stem-like cells called glioma initiating
cells (GICs). These cells have self-renewal capability and cause gliomagenesis. The GICs are
under the regulation of several signaling pathways including Shh, Notch, Wnt and BMI1.
Effective targeting of GICs could become a novel strategy to target glioma [10]. The 10p13
region is highly significant in brain tumorigenesis especially glioblastoma. BMI1 is part of the
polycomb repressive complex 1, which epigenetically regulates gene expression by acetyla‐
tion, methylation, and mono-ubiquitination of histones [11]. These modifications cause
transcriptional repression of differentiation and pluripotency of embryonic stem cells [12].
BMI1 is essential for the proliferation and transformation of primary glial cells. BMI1 deficient
glial cells have less proliferating and tumorigenic capacities. BMI1 is also involved in pathways
including proliferation, adhesion, and differentiation. All these pathways play a significant
contribution to stem cell renewal and glioblastoma development [13]. One report demonstrates
a high copy number of BMI1 in glioma samples [11]. Even, a murine tumor model showed a
role for BMI1 in the genesis of glioma and high fold expression of BMI1 in high-grade gliomas
[13]. BMI1 shows functional diversity in different cell types including embryonic stem cells
and mature neurons [12]. Moreover, BMI1 sometimes behaves as a tumor suppressor gene or
oncogene in different tumors. According to one study most of the glioma samples showed
BMI1 gene allelic imbalance. BMI1 negatively regulates p16 in astrocytoma. However, they
also suggest that BMI1 is not very significant for prognosis of astrocytic tumors [2]. Interest‐
ingly, BMI1 is considered as a transgene, which helps MYC to promote hematopoietic
malignancies [14-16]. High expression of BMI1 has been noted in brain tumors irrespective of
tumor grades [5]. BMI1 has a role in glioma and glioma stem cell growth which is both
dependent and independent of InK4a-Arf [13]. GBM showed an association of BMI1 overex‐
pression and enrichment in CD133+ cells [Xia et al., 2012]. Stable knockdown of BMI1 in GBM
reveals that BMI1 prevented the clonogenic nature of GBM cells and also these cells were not
able to develop brain tumors in vivo. Accordingly, BMI1 is a potent inhibitor of apoptosis in
CD133+ cells and of differentiation into neurons and astrocytes [17]. BMI1 is also capable to
inhibit alternate tumor suppressor pathways that attempt to compensate for INK4A-ARF/p53
deletion and hyperactivity of the PI3K/AKT pathway [17]. Interestingly, one study suggests
that BMI1 causes apoptotic resistance to glioma cells through the activation of IKK-Nuclear
factor-kB pathway and could therefore be a good prognostic factor for glioma [20]. IKK-
Nuclear factor-kB pathway is very active in high grade GBM and glioma cell lines [18, 19].
High expression of BMI1 protects brain tumor cells from cytotoxic reagents-induced apoptosis,
while attenuated BMI1 expression promotes apoptosis inducer factors. BMI1 also controls
apoptosis in glioma cell lines by activation of the IKK-NF-kB pathway and promoting anti-
apoptotic genes [20]. Co-expression of BMI1 and p65 protein, a subunit of NF-kB in glioma is
in favour of BMI1 and NF-kB pathways involvement in glioma chemoresistance. GBM is
resistant to all types of therapies. It has been postulated that most CD133+ cells are resistant
to gamma radiation via activation of DNA double-strand break (DSB) response mechanism,
including the participation of the ataxia-telangiectasia-mutated kinase gene (ATM). After
purification of BMI1 with DNA DSB responsive factors and nonhomologous end joining
(NHEJ) repair proteins in GBM cells [21], a BMI1 enrichment was observed after irradiation,
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being colocalized and co-purified with ATM and histone gammaH2AX. Deficient BMI1 glioma
cells showed inactive DNA DSB response, which promoted sensitivity of radiation in glioma
cells. Overexpressed BMI1 modulated the neural stem cells radiation resistance by enhancing
the ATM activity. Therefore, a combined effect of BMI1 inhibition together with radiation
therapy might efficiently target GBM stem cells [21]. Interestingly, a recent report suggested
that expression of BMI1 and c-Myc correlated in glioma. This finding further reveals that c-
Myc, either directly or indirectly, activates several epigenetic modulators including acetylase
GCN5 and polycomb-group (PcG) gene BMI1 [22, 23]. It is interesting to know that BMI1
promoter contains functional E-box and c-Myc binding regions [24, 25]. Moreover, c-Myc was
able to activate BMI1; and BMI1 further facilitated the oncogenic expression of c-Myc in
glioblastoma development [17]. It has been speculated that c-Myc and BMI1 might be good
biomarkers of glioblastoma due to their high expression and involvement in gliomagenesis.
Inhibition of both genes could give glioblastoma a greater sensitivity to combined anticancer
therapy. A recent study revealed that Tamoxifen (TAM) has the ability to reduce the expression
of neural stem cell markers, like Nestin, Bmi1 and Vimentin, in glioma cell lines. Moreover,
the action of TAM in glioma cells apotosis is assisted by prostate apoptosis response-4(par-4)
[26]. It has been published that AR-A 014418 inhibits GSK3 beta kinase activation which further
regulates the cancer escape pathway via downregulation of anti-apoptotic gene BMI1 [27].
5. BMI1 and miRNAs
Low expression of miRNA-128 was reported in GBM samples. High expression of miRNA-128
in GBM down-regulates ARP5 (ANGPTL 6), BMI1 and E2F-3a, factors which are key regulator
for brain cell proliferation [28]. miRNA-128 also targets BMI1 and down-regulates its expres‐
sion. Most of the glioma samples show less expression of miRNA-128. Overexpression of
miRNA-128 shows inhibition of GICs proliferation and self-renewable capacity [10]. Normal
brain has abundant expression of miRNA-124, however, miRNA-124 expression is diminished
during the development of glioma. Interestingly, overexpression of miRNA-124 reduced the
formation of neurospheres, the CD133+ cell subpopulation, and the expression of stem cells
markers like BMI1, Nanog and Nestin [29]. Smoothened inhibitor NPV-LDE-225 (Erismode‐
gib) inhibits BMI1 in GICs via upregulation of miRNA-128, miRNA-21 and miRNA-200 [30].
Interestingly, NPV-LDE-225 was used in topical cream for basal cell carcinoma treatment and
it inhibited the Shh pathway [31]. A recent study suggested that NPV-LDE-225 mediated
inhibition of Shh signaling downregulates Bmi1 via upregulation of miRNA-128 [30]. Another
study also suggested that polycomb repressor complex BMI1 is targeted by miRNA-128 in
glioma stem cells [32]. Another miRNA-218 also inhibited the expression of BMI1 which
further retarded glioma invasion, migration, and glioma stem cell renewal capability. Most
gliomas showed less expression of miRNA-218 and overexpression of miRNA-128, which
further inhibited glioma tumor characteristics. It was assumed that BMI1 is the downstream
target gene of miRNA-218. miRNA-218 regulates many genes which are involved in glioma
tumorigenesis [33]. Interestingly, we illustrate a model diagram for the role of BMI1 in
gliomagenesis (Figure 1).
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Figure 1. BMI1 networking in gliomagenesis
6. Role of BMI1 in medulloblastoma
Medulloblastoma is a primitive neuroectodermal tumor of the cerebellum. Medulloblastoma
is the most common pediatric malignant brain tumor, representing 20% of newly identified
CNS tumors in children [34]. Medulloblastoma is driven by several signaling pathways, among
which, Shh plays a critical role for the majority of these tumors [35, 36]. Mutations of the Shh
pathway regulators are present in about 20-25% of medulloblastomas [37]. Shh-driven
medulloblastoma showed high expression of BMI1. A recent study reveals the role of BMI1 in
Shh-driven medulloblastoma. Transgenic mice showed the expression of Shh signaling
activator SmoA1 with the help of glial fibrillary acidic protein (GFAP) promoter. They found
that SmoA1/BMI1+/+; SmoA1/BMI1+/-postnatal mice (p=26) between days P14 to P26 showed
prominent potential to develop medulloblastoma compared to SmoA1/BMI1-/-post natal mice
(n=6) [38]. Interestingly, cells with BMI1 deficiency BMI1-/- even in the presence of SmoA1
were non-proliferative compared to BMI1+/+ cells [38]. Two down-stream genes which are
inversely regulated by BMI1 in Shh-driven medulloblastoma development were reported.
Cyclin D1 expression was downregulated and cyclin-dependent kinase inhibitor p19Arf was
upregulated. Moreover, it was concluded that BMI1 is crucial for the Shh-driven medullo‐
blastoma development and that BMI1 facilitates medulloblastoma development de novo [38].
During embryonic development Shh signaling pathway regulates proliferation of granular
neuron precursors (GNPs). GNPs are progenitors for medulloblastoma development, com‐
prising the transient external granular layer of cerebellum [39]. BMI1 seems to promote the
expression of downstream target genes during cerebellum development [40]. BMI1-null mice
developed reduced cerebellum and impaired production of granular neurons. Altered
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expression of BMI1 in medulloblastoma as well as correlation of BMI1 expression and Shh
activation was reported in medulloblastoma [38, 41]. It was suggested that polycomb gene
expression could be used as a predictor of poor clinical outcome in medulloblastoma [42]. BMI1
overexpression caused cell proliferation and assisted Shh signaling driven tumorigenesis [43].
BMI1 expression and Shh ligand concentration were positively correlated during develop‐
ment. Chromatin immunoprecipitation experiments revealed that Shh signaling pathway
main transcriptional activator Gli1 preferentially binds to the promoter regions of BMI1.
Moreover, overexpression and downregulation of Gli1 controls high and low expression of
BMI1 respectively. Interestingly, BMI1 is not only a Shh-Gli1 downstream target gene but also
promotes a feedback mechanism which further activates Shh-Gli1 signaling. This finding
suggested that both BMI1 and Shh signaling pathways are mutually indispensable pathways
in brain tumor initiating cells (BTICs) of medulloblastoma [43]. One study reported that
overexpressed BMI1 was unable to induce tumors in mice from granule cell progenitors
(GCPs). Therefore, it was concluded that overexpression of BMI1 in GCP-derived human
medulloblastoma, could promote later stages of tumorigenesis and further sustain tumor cell
survival [44]. Apart from cell proliferation other characteristic of tumors include anti-apoptotic
nature and sustaining of high metabolic rate, both supported by high BMI1 and low TP53 levels
of expression which are characteristic of group 4 human medulloblastoma [44]. BMI1 overex‐
pression alone was not sufficient to induce medulloblastoma; however BMI1 overexpression
and loss of p53 induced medulloblastoma in mice, producing similar tumors to group 4 human
medulloblastomas [44]. Recently, medulloblastomas have been categorized in 4 subgroups on
the basis of prognosis and predicted therapeutics (Kool et al., 2012, Ramaswamy et al., 2013
and Gottardo et al., 2014). Group 1 and group 2 are under the good clinical outcome and
regulated by Shh and Wnt signaling, respectively [45]. Groups 3 and 4 medulloblastoma are
not Shh/Wnt signaling mediated tumors, have metastatic potencial, and poor patient outcome
and lack of known molecular pathways. Current gene expression analysis is unable to detect
self-renewal gene and brain tumor-initiating cells (BTIC) in group 3 and group 4 medullo‐
blastoma. BTICs constitute a minority of the tumor mass, and their detection can be difficult
in medulloblastoma. High BTIC promoted tumors to increase tumor aggressiveness and poor
patient outcome. They investigated the potential stem cells candidate genes among the
different subgroups of 251 human medulloblastoma samples from the 4 overlapping MB
transcriptional data bases (Amsterdam, Memphis, Toronto and Boston) and 74 nano-string
sub-grouped medulloblastoma (Vancouver) [45]. This analysis showed two crucial genes BMI1
and FoxG1, which presented abundant expression in non-Shh/wnt medulloblastoma groups.
These genes are responsible to promote MB stem cells and tumor initiation in mice [45]. We
also depicted a model for the different group of medulloblastoma development on the basis
of cell signaling pathways and gene expression profile (Figure 3). This study also identified a
reciprocal promoter in CD15+ medulloblastoma stem cells. The finding could be used as a
novel target therapy against BTIC self-renewal. They also found BMI1 is a downstream target
of FoxG1 and further promotes tumorigenicity. BMI1 also exerts feedback to FoxG1 expression
and facilitates in vivo tumor malignancy and enhances in vitro stem cell self-renewal capability.
Moreover, high expression of BMI1 can be considered as a strong molecular prognostic marker
in pediatric brain tumors. We attempted to show a model for the role of BMI1 in medullo‐
blastoma development (Figure 2).
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Figure 2. BMI1 networking in medulloblastoma development
Figure 3. Division of medulloblastoma on the basis of gene and cell signaling expression
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7. Conclusion
BMI1 is a very significant stem cell marker gene which contributes to the development of
glioblastoma and medulloblastoma. Therefore, the treatment of glioblastoma and medullo‐
blastoma would improve with the addition of BMI1 inhibitors. Moreover, high expression of
BMI1 could be used as one of the earliest markers to diagnose brain tumors.
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